SomatoKine. Insmed.
SomatoKine, a recombinant fusion of insulin-like growth factor-1 and its binding protein, BP-3, is being developed by Insmed (formerly Celtrix Pharmaceuticals) for the potential treatment of growth hormone insensitivity syndrome (GHIS), and as a potential injectable insulin sensitizer for the management of type 1 and type 2 diabetes in patients who are less sensitive to insulin therapy. By July 2002, the FDA had granted SomatoKine Orphan Drug status for the treatment of GHIS. Also at this time, a phase II trial in children suffering from GHIS was initiated. In September 2002, Insmed expected to initiate a further clinical trial in GHIS in early 2003, and planned to continue phase II development in type 1 and type 2 diabetes.